Delgocitinib cream (Anzupgo, Leo Pharma) performed well in teens with moderate to severe chronic hand eczema (CHE), according to the DELTA TEEN trial.
DELTA TEEN is a pivotal Phase 3 clinical trial with delgocitinib 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of adolescents (aged 12-17) with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate. Currently, no treatment options are approved specifically for moderate to severe CHE in the adolescent population. The trial met the primary endpoint with a statistically significant improvement in CHE symptoms after 16 weeks of treatment with delgocitinib compared to cream vehicle. Furthermore, the safety profile of delgocitinib was consistent with previous pivotal trials. DELTA TEEN is the fifth Phase 3 delgocitinib cream trial to achieve primary and all key secondary endpoints.
“Research on adolescents with CHE has revealed that the condition can considerably affect their quality of life, including psychosocial well-being, school performance and leisure activities,” says study author Sonja Molin, MD, an Academic Dermatologist at Charite Universitätsmedizin Berlinin Berlin, Germany, and Adjunct Associate Professor of Dermatology at Queen’s University in Kingston, Ontario, Canada, in a news release. “These findings further our understanding of how moderate to severe CHE manifests in adolescents and how to support this underserved patient group.”
Currently, delgocitinib cream is approved for adults in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate, and is under investigation in other markets, including the United States.
Detailed results from DELTA TEEN are planned to be submitted for scientific presentation and publication at a later date.
